Transgene SA has signed agreements giving its Chinese joint venture partner Tasly Biopharmaceuticals Co., Ltd. rights in Greater China to T601 and T101, two immunotherapeutics already under development by the companies' equally owned JV, full ownership of which will also be turned over to Tasly as part of the deal.
In return for the transfers, Transgene, part of Institut Mérieux, will receive an aggregate of $48m in newly issued Tasly...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

